Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833939 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| SCHEMBL20120060 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| SCHEMBL29833932 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| SCHEMBL24390712 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| Hydrochloric Acid SCHEMBL29833950 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| Hydrochloric Acid SCHEMBL29238713 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| SCHEMBL24390706 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| Hydrochloric Acid SCHEMBL29238805 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| SCHEMBL20119982 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMAPTKMT2AHTT | |
| SCHEMBL22358636 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398140-B2 | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20240382491-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-21 | — | — | US | claimed |
| CN-118251225-A | Methods of treating neurodegenerative diseases | PTC医疗公司 | 2024-06-25 | — | — | CN | claimed |
| US-20240041886-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | claimed |
| EP-4288441-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| US-20220135568-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | claimed |
| US-20240041886-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20220135568-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135568-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382491-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | SMN1; SMN2 35/4885LMNA 2030/4885MAPT 1/4885 |
| US-20240041886-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | SMN1; SMN2 4/4885LMNA 1647/4885MAPT 575/4885 |
| US-20220135568-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | DPYD, PTBP1, PABPC1 | SMN1; SMN2 24/4885LMNA 472/4885MAPT 1455/4885 |
| US-12398140-B2 | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia | DPYD, PTBP1, SARNP | SMN1; SMN2 22/4885LMNA 392/4885MAPT 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.